Brokerages Set Perrigo Company plc (NYSE:PRGO) Target Price at $19.33

Shares of Perrigo Company plc (NYSE:PRGO) have been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $19.3333.

Several analysts have recently weighed in on PRGO shares. Argus upgraded shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Canaccord Genuity Group dropped their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Perrigo in a report on Monday, December 22nd. Finally, Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th.

Perrigo Stock Performance

Shares of NYSE PRGO opened at $10.75 on Monday. The business has a fifty day simple moving average of $14.19 and a 200 day simple moving average of $16.99. The company has a current ratio of 2.76, a quick ratio of 1.63 and a debt-to-equity ratio of 1.23. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -1.05, a PEG ratio of 1.29 and a beta of 0.41. Perrigo has a one year low of $10.65 and a one year high of $29.08.

Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The firm’s quarterly revenue was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Sell-side analysts expect that Perrigo will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd will be given a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 10.8%. The ex-dividend date is Monday, March 2nd. Perrigo’s dividend payout ratio is -11.28%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PRGO. EverSource Wealth Advisors LLC boosted its stake in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after purchasing an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares in the last quarter. UMB Bank n.a. increased its position in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after purchasing an additional 1,213 shares in the last quarter. Huntington National Bank lifted its holdings in Perrigo by 237.8% during the 2nd quarter. Huntington National Bank now owns 1,054 shares of the company’s stock valued at $28,000 after purchasing an additional 742 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in Perrigo in the fourth quarter valued at about $28,000. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.